About: Smoldering multiple myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Smoldering multiple myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1980

Attributes	Values
rdf:type	Item
description	наукова стаття, опублікована в червні 1980 (uk) im Juni 1980 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1980 (ast) scientific article published on 01 June 1980 (en)
publication date	wds:Q71193461-7CBFDB7C-8C1E-405B-8A21-C613DACFF107
publication date	1980-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71193461-FFD41D48-AB50-41BA-A6AD-FB6867AEE738
language of work or name	English
author name string	wds:Q71193461-405F3661-F618-40D0-A755-37E766A601B8 wds:Q71193461-FCD37577-DFA0-4232-B5B0-5DB79C870C5D
author name string	Kyle RA Greipp PR
rdfs:label	Smoldering multiple myeloma (en)
skos:prefLabel	Smoldering multiple myeloma (en)
name	Smoldering multiple myeloma (en)
title	wds:Q71193461-DBD54178-E33C-4699-8F8D-202043F54959
title	Smoldering multiple myeloma (en)
page(s)	wds:Q71193461-78A11686-3804-4917-BC53-37FDB26CCD56
page(s)	1347-1349
instance of	wds:Q71193461-390BCEBB-1FCB-4F1D-B739-142C1B96DC8A
instance of	scholarly article
main subject	wds:Q71193461-80F65E41-4DA3-478A-AB3C-5372C4472B58
main subject	multiple myeloma
PubMed ID	wds:Q71193461-31D12A60-7075-4C1B-9C09-60396D9B16BF
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7374679
PubMed ID	7374679
published in	wds:Q71193461-96AEFBB4-6444-4EB3-852E-AD1742C0F928
published in	The New England Journal of Medicine
issue	wds:Q71193461-1F00B49A-1FFC-43E0-B0E4-F3275D1152A5
volume	wds:Q71193461-F38D1277-D762-4C7C-85FB-48789245BA2C
issue	24
volume	302
number of pages	wds:Q71193461-CE55D257-63E0-47E1-AA3E-A67595D03593
number of pages	3 (xsd:decimal)
DOI	wds:Q71193461-BB92BFF3-2291-4FBC-8160-7C12AA121587
DOI	http://dx.doi.org/10.1056/NEJM198006123022405
DOI	10.1056/NEJM198006123022405
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71193461
is cites work of	Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease Monoclonal gammopathies of undetermined significance: a review Thalidomide as initial therapy for early-stage myeloma Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Smoldering multiple myeloma requiring treatment: time for a new definition? Thalidomide for previously untreated indolent or smoldering multiple myeloma Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation Multiple myeloma wd:Q28082855 How I treat smoldering multiple myeloma Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases Monoclonal gammopathy of undetermined significance (MGUS). Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective Multiple myeloma precursor disease. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden New approaches to smoldering myeloma Monoclonal gammopathies of undetermined significance Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance Racial disparities in incidence and outcome in multiple myeloma: a population-based study Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Importance of quantitative histology of bone changes in monoclonal gammopathy "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up Renal lesions in plasma cell dyscrasias: ultrastructural observations The monoclonal gammopathies (paraproteins). Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies Dilemmas in treating smoldering multiple myeloma p53 gene mutations in multiple myeloma. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status [Analysis of prognostic factors in plasmacytoma] Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients? Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy Plasma cell dyscrasias: current status MGUS to myeloma: a mysterious gammopathy of underexplored significance Multiple Myeloma. Diagnostic challenges and standard therapy A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group. Concomitant occurrence of MALT lymphoma and multiple myeloma. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study Multiple myeloma epidemiology and survival: A unique malignancy Histologic classification and staging of multiple myeloma Prognostic factors in multiple myeloma The multiple myelomas - current concepts in cytogenetic classification and therapy. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Antigen stimulated IgM secretion by circulating B lymphocytes in patients with benign and malignant IgG gammopathy. Relationship to stage of disease Immunoglobulin secretion by peripheral blood and bone marrow B cells in patients with multiple myeloma. Studies by the reverse haemolytic plaque assay Differentiation of benign monoclonal gammopathy and smouldering multiple myeloma from frank myeloma The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group Monoclonal gammopathy and multiple myeloma in the elderly Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software